Critical Diagnostics signs agreements with four new European distributors

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.

“Ever more convincing clinical data is coming in on ST2's value in prognosis and care of heart failure patients. In these days of austerity, an assay that can actively improve patient outcomes while reducing overall health care costs is in great demand.”

"Just recently, one of the largest hospitals in Barcelona established a protocol of using Presage ST2 Assay as part of the standard of care for managing patients with heart failure," says James Snider, President of Critical Diagnostics. "Ever more convincing clinical data is coming in on ST2's value in prognosis and care of heart failure patients. In these days of austerity, an assay that can actively improve patient outcomes while reducing overall health care costs is in great demand."

Source Critical Diagnostics